Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for relapse prevention in severe alcohol use disorder (phase II)
2015-000222-11Phase 2Completed
- Sponsor
- University College London
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in alcohol use disorder (AUD) comparing Ketalar + relapse-prevention therapy with Placebo + relapse-prevention therapy (2 arms). Primary endpoints: Relapse rates at 6 months and Percentage days abstinent at 6 months. Started Jul 2020; status: completed.
02
Drugs
ketamine
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on 2015-000222-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000222-11.